Skip to main content
SpringerLink
Log in

Ceftriaxone: In vitro activity against 410 bacterial isolates compared with cefotaxime

Ceftriaxon: In-vitro-Aktivität gegenüber 410 Bakterien-Isolaten im Vergleich zu Cefotaxim

  • Brief Communication
  • Published:
Infection Aims and scope Submit manuscript

Summary

Thein vitro activity of the two new cephalosporins, cefotaxime and ceftriaxone, against 410 bacterial isolates was compared using an agar dilution method. Both compounds were highly active againstEnterobacteriaceae, including indole-positiveProteus andProvidencia; the great majority of the isolates were inhibited by 0.06 mg/l of either drug. Activity againstPseudomonas aeruginosa andStaphylococcus aureus was moderate, and enterococci were resistant. AllStreptococcus pneumoniae, Streptococcus pyogenes andHaemophilus influenzae isolates were susceptible to 0.03 mg/l of either drug. The isolates belonging to theBacteroides fragilis group were inhibited over a wide range of concentrations and some were highly resistant (MIC ≥ 64 mg/l). There were no significant differences in the antibacterial activity of the two drugs against our isolates. Both drugs may be of potential use in the treatment of serious infections caused byEnterobacteriaceae; they may prove to be a useful alternative to the aminoglycosides.

Zusammenfassung

Die beiden neuen Cephalosporine Cefotaxim und Ceftriaxon wurden mittels Agar-Dilutionsmethode in ihrerIn-vitro-Aktivität gegenüber 410 Bakterien-Isolaten verglichen. Beide Verbindungen wiesen hohe Aktivität gegenüberEnterobacteriaceae auf, einschließlich indolpositiverProteus- undProvidencia-Stämme; beide Medikamente hemmten die überwiegende Mehrzahl der Isolate bei einer Konzentration von 0,06 mg/l. Die Wirksamkeit gegenüberPseudomonas aeruginosa undStaphylococcus aureus war nur mäßig, Enterokokken waren resistent. Alle Isolate vonStreptococcus pneumoniae, Streptococcus pyogenes undHaemophilus influenzae waren empfindlich gegenüber beiden Medikamenten in einer Konzentration von 0,03 mg/l. Die Hemmkonzentrationen für Isolate derBacteroides fragilis-Gruppe variierten stark, manche Stämme waren hochresistent (MHK ≥ 64 mg/l). Die beiden Medikamente wiesen gegenüber den von uns geprüften Isolaten keine signifikanten Unterschiede auf. Beide können in der Behandlung schwere Infektionen durchEnterobacteriaceae von Nutzen sein und sich als brauchbare Alternative für die Aminoglykoside darstellen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literature

  1. Editorial: Moxalactam. Lancet II (1981) 23–24.

  2. Neu, H. C., Meropol, N. J., Fu, K. P. Antibacterial activity of ceftriaxone (Ro 13-9904), a β-lactamase-stable cephalosporin. Antimicrob. Agents Chemother. 19 (1981) 414–423.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schrinner, E., Limbert, M., Penasse, L., Lutz, A. Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro andin vivo). J. Antimicrob. Chemother. 6 Suppl. A (1980) 25–30.

    Article  CAS  PubMed  Google Scholar 

  4. Closs, O., Digranes, A. Rapid identification of prompt lactosefermenting genera within the familyEnterobacteriaceae. Acta Pathol. Microbiol. Scand. Sect. B, 79 (1971) 673–678.

    CAS  Google Scholar 

  5. Cowan, S. T. (ed.): Cowan and Steel's manual for the identification of medical bacteria. 2nd ed. Cambridge University Press, Cambridge, London, New York, Melbourne 1975.

    Google Scholar 

  6. Ericsson, H. M., Sherris, J. S. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol. Microbiol. Scand. Sect. B, Suppl. 217 (1971) 11–47.

    Google Scholar 

  7. Digranes, A., Dibb, W. L., Østervold, B. Thein vitro activity of netilmicin against 357 clinical isolates ofEnterobacteriaceae, Pseudomonas aeruginosa andStaphylococcus aureus. Scand. J. Infect. Dis. Suppl. 23 (1980) 30–33.

    CAS  PubMed  Google Scholar 

  8. Angehrn, P., Probst, P. J., Reiner, R., Then, R. L. Ro 13-9904, a long-acting broad spectrum cephalosporin:In vitro andin vivo studies. Antimicrob. Agents Chemother. 18 (1980) 913–921.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jorgensen, J. H., Crawford, S. A., Alexander, G. A. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli. Antimicrob. Agents. Chemother. 17 (1980) 937–942.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hinkle, A. M., Bodey, G. P. In vitro evaluation of Ro 13-9904. Antimicrob. Agents Chemother. 18 (1980) 574–578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Prince, A. S., Neu, H. C. Activities of new beta-lactam antibiotics against isolates ofPseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob. Agents Chemother. 20 (1981) 545–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hamilton-Miller, J. M. T., Brumfitt, W., Reynolds, A. V. Cefotaxime (HR 756) a new cephalosporin with exceptional broad spectrum activityin vitro. J. Antimicrob. Chemother. 4 (1978) 437–444.

    Article  CAS  PubMed  Google Scholar 

  13. Ng, W. S., Chau, P. Y., Arnold, K. In vitro susceptibility ofHaemophilus influenzae andNeisseria gonorrhoeae to Ro 13-9904 in comparison with other β-lactam antibiotics. Antimicrob. Agents Chemother. 19 (1981) 925–926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shannon, K., King, A., Warren, C., Phillips, I. In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases. Antimicrob. Agents Chemother. 18 (1980) 292–298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cadoz, M., Denis, F., Peyramond, D., Diop Mar, I.: Experience with Rocephin (Ro 13-9904) in bacterial meningitis. Clinical, bacteriological and pharmacological results in 62 patients. Abstracts, 12th International Congress of Chemotherapy, Florence, Italy, 19–24 July 1981, p. 221.

  16. Toyonaga, Y., Kurosu, Y., Hori, M.: Basic and clinical evaluation of cefotaxime against purulent meningitis in children. Abstracts. 12th International Congress of Chemotherapy, Florence, Italy, 19–24 July 1981, p. 198.

  17. Drasar, F. A., Farrell, W., Howard, A. J., Hince, C., Leung, T., Williams, J. D. Activity of HR 756 againstHaemophilus influenzae, Bacteroides fragilis and gram-negative rods. J. Antimicrob. Chemother. 4 (1978) 445–450.

    Article  CAS  PubMed  Google Scholar 

  18. Neu, H. C., Aswapokee, N., Aswapokee, P., Fu, K. P. HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 15 (1979) 273–281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Beskid, G., Christenson, J. G., Cleeland, R., DeLorenzo, W., Trown, P. W. In vivo activity of ceftriaxone (Ro 13-9904), a new broad spectrum semisynthetic cephalosporin. Antimicrob. Agents Chemother. 20 (1981) 159–167.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Seddon, M., Wise, R., Gillett, A. P., Livingston, R. Pharmacokinetics of Ro 13-9904, a broad spectrum cephalosporin. Antimicrob. Agents Chemother. 18 (1980) 240–242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Haukeland Hospital, N-5016, Haukeland Sykehus, Norway

    A. Digranes, E. Benonisen &  W. L. Dibb

Authors
  1. A. Digranes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Benonisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. L. Dibb
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Digranes, A., Benonisen, E. & Dibb, W.L. Ceftriaxone: In vitro activity against 410 bacterial isolates compared with cefotaxime. Infection 10, 307–309 (1982). https://doi.org/10.1007/BF01640881

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01640881

Keywords

Search

Navigation